
A failed drug trial by Australia's third-largest public company has helped drag the ASX into the red at the start of the week.
The benchmark S&P/ASX200 index finished Monday down 29.9 points, or 0.39 per cent, to 7,614.9, while the broader All Ordinaries dropped 24.4 points, or 0.31 per cent, to 7,860.3.